Positron emission tomography scanning in malignant melanoma: Clinical utility in patients with Stage III disease

Cancer

Volumn 89, Issue 5, 2000, Pages 1019-1025

  Tyler, Douglas S ^a   Onaitis, Mark ^a   Kherani, Aftab ^a   Hata, Ankie ^a   Nicholson, Evelyn ^a   Keogan, Mary ^a   Fisher, Samuel ^a   Coleman, Edward ^a   Seigler, Hiliard F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

2 fluorine 18; 2 fluoro 2 deoxy D glucose (FDG); In transit disease; Melanoma; Metastatic; Positron emission tomography (PET) scan

Indexed keywords

FLUORODEOXYGLUCOSE;

ARTICLE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RADIATION DOSE; RELIABILITY; TREATMENT PLANNING;

EID: 0034284334     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000901)89:5<1019::AID-CNCR11>3.0.CO;2-0     Document Type: Article

References (22)

1. Cancer detection with whole-body PET using 2-[18F] fluoro-2-deoxy-D-glucose
2. Cost-effectiveness of PET imaging in clinical oncology
3. Positron emission tomography in oncology: General acceptance of its role is overdue
4. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET)
5. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma
6. Positron emission tomography in the detection and management of metastatic melanoma
7. Malignant melanoma: Staging with whole body positron emission tomography and 2-(F-18)-fluoro-2-deoxy-D-glucose
8. Staging of metastatic melanoma by whole body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose
9. Positron emission tomography and ultrasonography: A comparative retrospective study assessing the diagnostic validity in lymph node metastasis of malignant melanoma
10. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography
11. Effectiveness of positron emission tomography for the detection of melanoma metastasis
12. Prospective evaluation of 2 [18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma
13. Positron emission tomography plus serum TA90 immune complex assay for detection of occult metastatic melanoma
14. Performance characteristics of a whole-body PET scanner
15. A method for post injection PET transmission measurements with a rotating source
16. Efficient stereospecific synthesis of no-carrier-added 2 -[18F]-fluror-2-deoxy-D-glucose using aminopolyether-supported nucleophilic substitution
17. Computed tomography in evaluation of patients with stage III melanoma
18. Computed tomography in staging patients with melanoma metastatic to the regional nodes
19. Role of computed tomography in the staging of patients with local-regional metastases of melanoma
20. Prospective study of fluorodeoxy-glucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel lymph node biopsy
21. Initial assessment of positron emission tomography for the detection of subclinical regional lymphatic metastasis in melanoma